Oral Mucositis - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 99 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Oral Mucositis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Oral Mucositis - Pipeline Review, H2 2014', provides an overview of the Oral Mucositis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oral Mucositis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oral Mucositis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Oral Mucositis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Oral Mucositis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oral Mucositis Overview 8
Therapeutics Development 9
Pipeline Products for Oral Mucositis - Overview 9
Pipeline Products for Oral Mucositis - Comparative Analysis 10
Oral Mucositis - Therapeutics under Development by Companies 11
Oral Mucositis - Therapeutics under Investigation by Universities/Institutes 13
Oral Mucositis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Oral Mucositis - Products under Development by Companies 17
Oral Mucositis - Products under Investigation by Universities/Institutes 18
Oral Mucositis - Companies Involved in Therapeutics Development 19
Daewoong Pharmaceutical Co., Ltd. 19
Soligenix, Inc. 20
Sucampo Pharmaceuticals, Inc. 21
Spectrum Pharmaceuticals, Inc. 22
Colby Pharmaceutical Company 23
ActogeniX NV 24
Alder Biopharmaceuticals Inc. 25
Promedior, Inc. 26
ProCertus BioPharm Inc. 27
GliaMed, Inc. 28
Cellceutix Corporation 29
Vicus Therapeutics, LLC 30
Otsuka Holdings Co., Ltd. 31
Laila Pharmaceuticals Pvt. Ltd. 32
Oral Mucositis - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
nepidermin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
clonidine hydrochloride ER - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
clazakizumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
rebamipide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pralatrexate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SGX-942 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LP-00409 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AG-013 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
cobiprostone - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
brilacidin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
GC-4403 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GM-1485 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PRM-151 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Gene Therapy for Oral Mucositis - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Regenasyn - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GC-4419 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AP-002 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
AP-001 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OralX - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
(captopril + teprenone) - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
JVRSOD - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Oral Mucositis - Recent Pipeline Updates 72
Oral Mucositis - Dormant Projects 89
Oral Mucositis - Discontinued Products 90
Oral Mucositis - Product Development Milestones 91
Featured News & Press Releases 91
Aug 11, 2014: Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis 91
May 05, 2014: BioAlliance Pharma announces major achievements on Validive: Enrollment completion in the international Phase II trial with Validive in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting 91
Apr 07, 2014: Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer 92
Feb 18, 2014: Access Pharmaceuticals Announces Publication Of MuGard Clinical Data In Cancer Journal 92
Jan 23, 2014: FDA Grants Validive with a Fast Track Designation for the Prevention and Treatment of Oral Mucositis Induced by Anticancer Treatments 94
Dec 20, 2013: Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis With US FDA 94
Dec 05, 2013: Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 95
Sep 30, 2013: BioAlliance Pharma : First Meeting of the International Advisory Board on Oral Mucositis and Development of Validive 95
Jun 10, 2013: BioAlliance Pharma Initiates Phase II Clinical Trial With Validive In US 96
Jun 03, 2013: Soligenix's SGX942 Receives FDA Fast Track Designation For Treatment Of Oral Mucositis In Patients With Head And Neck Cancer 96
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99

List of Tables
Number of Products under Development for Oral Mucositis, H2 2014 9
Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 19
Oral Mucositis - Pipeline by Soligenix, Inc., H2 2014 20
Oral Mucositis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2014 21
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 22
Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H2 2014 23
Oral Mucositis - Pipeline by ActogeniX NV, H2 2014 24
Oral Mucositis - Pipeline by Alder Biopharmaceuticals Inc., H2 2014 25
Oral Mucositis - Pipeline by Promedior, Inc., H2 2014 26
Oral Mucositis - Pipeline by ProCertus BioPharm Inc., H2 2014 27
Oral Mucositis - Pipeline by GliaMed, Inc., H2 2014 28
Oral Mucositis - Pipeline by Cellceutix Corporation, H2 2014 29
Oral Mucositis - Pipeline by Vicus Therapeutics, LLC, H2 2014 30
Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 31
Oral Mucositis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H2 2014 32
Assessment by Monotherapy Products, H2 2014 33
Assessment by Combination Products, H2 2014 34
Number of Products by Stage and Target, H2 2014 36
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Oral Mucositis Therapeutics - Recent Pipeline Updates, H2 2014 72
Oral Mucositis - Dormant Projects, H2 2014 89
Oral Mucositis - Discontinued Products, H2 2014 90